Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Abi Berger Statins have an effect on the immune system that is completely
independent of their conventional use in reducing cholesterol levels.
Scientists in Switzerland have elucidated the mechanism by which
statins seem able to confer benefit on patients receiving heart
transplants. Their observations may lead to a reduction in the heavy
use of potent drugs such as cyclosporin for all transplant patients
(Nature Medicine 2000;6:1399-402).
Whereas the beneficial effects of statins on lipids in the
cardiovascular system are well known, it is also becoming clear that
statins can influence the immune system. When it was first observed, in
1995, that giving statins to heart transplant patients improved their
survival rates compared with treatment with placebo, it was put down to
the lipid lowering effects of the drugs, but it is now thought that the
drugs also modulate the immune system.
Dr François Mach, associate professor of medicine, and his colleagues
at Geneva Medical School, have reported the hitherto undetected
anti-inflammatory effects of statins using an in vitro model.
Their model suggests that statins shut down the alarm systems usually
present on antigen presenting cells, making foreign tissues less likely
to trigger an immune response against them. The statin mechanism
involves the expression of major histocompatibility complex class II
(MHC-II) molecules. MHC-II cells are responsible for presenting foreign
antigens on the surface of immune cells.
Dr Mach's team have discovered that, although statins do not influence
the basic expression of MHC-II molecules, they do seem to be able to
repress the MHC-II molecules that are induced by foreign tissue. They
do this by blocking the ability of interferon gamma, a cytokine, which
activates antigen presenting cells to express MHC-II on their surface.
"This is more of an immune repression, rather than immune
suppression," explains Dr Mach. "It doesn't necessarily mean we can expect to replace cyclosporin with a statin, but we may be able to
use statins to reduce the dose of cyclosporin that is needed."
Statins have far fewer and much milder side effects than cyclosporin.
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care